Your browser doesn't support javascript.
loading
Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events.
Makunts, Tigran; Burkhart, Keith; Abagyan, Ruben; Lee, Peter.
Afiliação
  • Makunts T; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States of America.
  • Burkhart K; Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, United States of America.
  • Abagyan R; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States of America.
  • Lee P; Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, United States of America.
PLoS One ; 17(2): e0263402, 2022.
Article em En | MEDLINE | ID: mdl-35143542
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados Idioma: En Ano de publicação: 2022 Tipo de documento: Article